Company Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.
It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd.
The company was founded in 2010 and is headquartered in Los Angeles, California.
| Country | United States |
| IPO Date | Apr 24, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 185 |
| CEO | Alan H. Auerbach |
Contact Details
Address: 10880 Wilshire Boulevard Los Angeles, California United States | |
| Website | https://www.pumabiotechnology.com |
Stock Details
| Ticker Symbol | PBYI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401667 |
| CUSIP Number | 74587V107 |
| ISIN Number | US74587V1070 |
| Employer ID | 77-0683487 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary |
| Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer |
| Douglas Hunt B.Sc., FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer |
| Jeffrey Jerome Ludwig | Chief Commercial Officer |
| Mariann Ohanesian | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 16, 2024 | 8-K | Current Report |